FiercePharma6h
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
STAT5h
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of its HPV vaccine, Gardasil, to reach $11 billion by 2030. The result: a 10% ...
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Merck beats estimates on fourth-quarter on earnings—but stock slides pre-market on tepid 2025 guidance
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
Merck Stock Plunges 9.5% After China Halt--Is This the Beginning of Bigger Trouble?
Gardasil shipment pause, weak guidance, and looming Keytruda risks send investors scrambling--can Merck turn things around?
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
devdiscourse9h
Key Developments in Global Health: Merck, Pfizer, and Innovative Vaccines
This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...